Integra LifeSciences (NASDAQ:IART) Stock Price Down 4.3% – Time to Sell?

Integra LifeSciences Holdings Co. (NASDAQ:IART)’s share price was down 4.3% during trading on Wednesday . The company traded as low as $22.71 and last traded at $22.92. 50,096 shares traded hands during mid-day trading, a decline of 92% from the average session volume of 656,643 shares. The stock had previously closed at $23.95.

Analyst Ratings Changes

Separately, Morgan Stanley started coverage on Integra LifeSciences in a research note on Monday, December 2nd. They set an “underweight” rating and a $20.00 target price for the company. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $23.00.

Integra LifeSciences Trading Up 0.1 %

The firm has a market cap of $1.72 billion, a P/E ratio of -247.42, a PEG ratio of 0.73 and a beta of 1.23. The company’s 50 day moving average is $23.81 and its two-hundred day moving average is $21.94. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.12. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company had revenue of $442.65 million during the quarter, compared to analysts’ expectations of $445.15 million. During the same quarter in the prior year, the company posted $0.89 EPS. The business’s revenue was up 11.5% on a year-over-year basis. On average, sell-side analysts predict that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Institutional Investors Weigh In On Integra LifeSciences

Large investors have recently modified their holdings of the stock. Sachem Head Capital Management LP acquired a new stake in Integra LifeSciences in the 3rd quarter valued at $44,153,000. Paradigm Capital Management Inc. NY boosted its stake in shares of Integra LifeSciences by 170.3% in the 4th quarter. Paradigm Capital Management Inc. NY now owns 1,431,100 shares of the life sciences company’s stock valued at $32,457,000 after purchasing an additional 901,600 shares in the last quarter. Capital Research Global Investors grew its holdings in shares of Integra LifeSciences by 7.4% in the 4th quarter. Capital Research Global Investors now owns 1,400,559 shares of the life sciences company’s stock worth $31,765,000 after purchasing an additional 95,944 shares during the last quarter. Lord Abbett & CO. LLC increased its position in shares of Integra LifeSciences by 86.8% during the 4th quarter. Lord Abbett & CO. LLC now owns 1,332,031 shares of the life sciences company’s stock worth $30,210,000 after purchasing an additional 618,773 shares in the last quarter. Finally, Soleus Capital Management L.P. bought a new position in Integra LifeSciences during the 4th quarter valued at about $28,940,000. 84.78% of the stock is currently owned by institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.